Literature DB >> 10856276

Physiology and pathophysiology of the adipose tissue renin-angiotensin system.

S Engeli1, R Negrel, A M Sharma.   

Abstract

The renin-angiotensin system has long been recognized as an important regulator of systemic blood pressure and renal electrolyte homeostasis, and local renin-angiotensin systems have also been implicated in pathological changes of organ structure and function by modulation of gene expression, growth, fibrosis, and inflammatory response. Recently, substantial data have been accumulated in support of the notion that adipose tissue, besides other endocrine functions, also hosts a local renin-angiotensin system. In the first part of this review, we describe the components of the adipose tissue renin-angiotensin system in human and rodent animal models with respect to regulation of angiotensinogen expression and secretion, formation of angiotensin peptides, and the existence of angiotensin II receptors. In the second part, we describe the role of the adipose tissue renin-angiotensin system in the process of adipogenic differentiation and in the regulation of body weight. We also detail the differential regulation of the adipose tissue renin-angiotensin system in obesity and hypertension and thereby also speculate on its possible role in the development of obesity-associated hypertension. Although some findings on the adipose tissue renin-angiotensin system appear to be confusing, its involvement in the physiology and pathophysiology of adipose tissue has been confirmed by several functional studies. Nevertheless, future studies with more carefully described phenotypes are necessary to conclude whether obesity (by stimulation of adipogenic differentiation) and hypertension are associated with changes of renin-angiotensin system activity in adipose tissue. If so, the physiological relevance of this system in animal models and humans may warrant further interest.

Entities:  

Mesh:

Year:  2000        PMID: 10856276     DOI: 10.1161/01.hyp.35.6.1270

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  107 in total

Review 1.  Complex interactions in complex traits: obesity and asthma.

Authors:  K G Tantisira; S T Weiss
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 2.  New developments in mechanisms of obesity-induced hypertension: role of adipose tissue.

Authors:  A M Sharma; S Engeli; T Pischon
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 3.  The global epidemic of obesity: are we becoming more sympathetic?

Authors:  Kevin P Davy
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

4.  Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction.

Authors:  Christy S Carter; Leanne Groban
Journal:  Aging health       Date:  2008-02-01

5.  Adipokine expression in brown and white adipocytes in response to hypoxia.

Authors:  A Wree; A Mayer; S Westphal; A Beilfuss; A Canbay; R R Schick; G Gerken; P Vaupel
Journal:  J Endocrinol Invest       Date:  2011-09-27       Impact factor: 4.256

6.  Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure.

Authors:  Helge Müller-Fielitz; Antonie Markert; Christian Wittmershaus; Friedrich Pahlke; Olaf Jöhren; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-03       Impact factor: 3.000

Review 7.  Role of ACE inhibitors in treating hypertensive diabetic patients.

Authors:  Dmitri Kirpichnikov; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

8.  Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

Authors:  Yau-Sheng Tsai; Hyo-Jeong Kim; Nobuyuki Takahashi; Hyung-Suk Kim; John R Hagaman; Jason K Kim; Nobuyo Maeda
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values.

Authors:  Aldo S Villecco; Cinzia Cocci; Maurizio Di Emidio
Journal:  Curr Ther Res Clin Exp       Date:  2004-03

Review 10.  Targeting hypertension in patients with cardiorenal metabolic syndrome.

Authors:  Edward Rojas; Manuel Velasco; Valmore Bermúdez; Zafar Israili; Peter Bolli
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.